TRI-SOLFEN DIN 02528223
Health Canada record
| Active ingredient(s) | LIDOCAINE HYDROCHLORIDE MONOHYDRATE 40.6 MG; BUPIVACAINE HYDROCHLORIDE 4.2 MG; EPINEPHRINE BITARTRATE 0.025 MG; CETRIMIDE 5 MG |
|---|---|
| Dosage form | Solution |
| Route | Topical |
| Schedule | NON-PRESCRIPTION DRUGS |
| Class | Veterinary |
| ATC | |
| Original market date | 06-Mar-2023 |
| Current status date | 06-Mar-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Dechra Veterinary Products Inc. — licence 102149, currently licensed, last inspection rating C (2025-05-13).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28425 | 2022-06-21 | New Drug Submission (NDS) |
International API supply for LIDOCAINE HYDROCHLORIDE MONOHYDRATE
11 valid EDQM Certificates of Suitability from 11 holders.
Request a quote for TRI-SOLFEN